Special report: current and evolving strategies in the treatment of age-related macular degeneration
BlueCross BlueShield Association
Record ID 32006000035
English
Authors' objectives:
This special report aims to provide an understanding of emerging therapies in the context of: 1) contemporary treatment options and 2) the underpinnings on which age-related macular degeneration (AMD) treatments are based.
Authors' recommendations:
Deciphering at least part of the underlying pathophysiology of AMD has brought therapies into the realm of angiostatic agents. Yet as technologies improve our understanding and provide additional treatments for AMD, more broadly portraying the impact of therapies on participants' lives in clinical trials could enable patients and providers to better assess therapeutic efficacy.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Laser Coagulation
- Photochemotherapy
- Antioxidants
- Macular Degeneration
- Vascular Endothelial Growth Factor A
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.